Gadofosveset
![]() | |
Clinical data | |
---|---|
Trade names | Vasovist, Ablavar |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C33H40GdN3Na3O15P |
Molar mass | 975.88 g·mol−1 |
3D model (JSmol) | |
| |
|
Gadofosveset (trade names Vasovist, Ablavar) is a gadolinium-based MRI contrast agent. It was used as the trisodium salt monohydrate form.[2][3] It acts as a blood pool agent by binding to human serum albumin. The manufacturer (Lantheus Medical) discontinued production in 2017 due to poor sales.[4]
Gadofosveset consists of a gadolinium cation bound to the chelating agent fosveset. It facilitates high-resolution magnetic resonance angiography.[5] Ferumoxytol (trade names Feraheme, Rienso), an intravenous iron-replacement therapy, has been shown to potentially be superior to gadofosveset as a blood pool agent for MR venography in pediatric patients.[6]
References
[edit]- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ DailyMed: Vasovist
- ^ Drugs.com: Ablavar
- ^ Bell D, Morgan M. "Gadofosveset trisodium". Radiopaedia. radiopaedia.org. Retrieved 2018-08-28.
- ^ Sabach AS, Bruno M, Kim D, Mulholland T, Lee L, Kaura S, Lim RP (June 2013). "Gadofosveset trisodium: abdominal and peripheral vascular applications". AJR. American Journal of Roentgenology. 200 (6): 1378–86. doi:10.2214/AJR.12.8991. PMID 23701079.
- ^ Shahrouki P, Khan SN, Yoshida T, Iskander PJ, Ghahremani S, Finn JP (March 2022). "High-resolution three‑dimensional contrast‑enhanced magnetic resonance venography in children: comparison of gadofosveset trisodium with ferumoxytol". Pediatric Radiology. 52 (3): 501–512. doi:10.1007/s00247-021-05225-2. PMC 8857136. PMID 34936018.